Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by B. López.
Actas Urologicas Espanolas | 2014
F.J. Díaz; E. de la Peña; V. Hernández; B. López; J.M. De La Morena; M.D. Martín; I. Jiménez-Valladolid; C. Llorente
OBJECTIVE To assess the safety of hospital discharge 24 hours after laparoscopic radical prostatectomy and to identify possible factors associated with longer hospital stays. MATERIAL AND METHODS Retrospective study of patients diagnosed with localized prostate cancer underwent to laparoscopic radical prostatectomy consecutively between May of 2007 and December of 2010. Those patients who met the following requirements were discharged in less than 24 hours: absence of complications, drainage debit minor than 50 cc, normal oral tolerance, no significant bladder haematuria and good functional recovery. Logistic regression analysis was conducted in order to assess the possible associated variables with longer hospital stays. RESULTS A total of 266 patients were analysed. The follow-up median was 34 months. Eighty patients (30.1%) were discharged in less than 24 hours. Average stay (SD) of all series was 2.9 days (3.08). Solely HTA, neurovascular bundles sparing and the development of lymphadenectomy were statistically significant between both groups in univariate analysis (discharge<24 hours vs. discharge>24 hours). In multivariate analysis, only HTA (OR=1.98 [CI 95%:1.13-3.47], P=.016) and lymphadenectomy performance (OR=2.56 [CI 95%:1.18-5.56] P=.017) were independent predictive variables of hospital stays longer than 24 hours. CONCLUSIONS Early hospital discharge of patients underwent to LRP is feasible and safe. In our series, the lymphadenectomy performance and the HTA were associated factors to longer hospital stay.
Actas Urologicas Espanolas | 2015
A. Guijarro; V. Hernández; B. López; Carlos Capitán; E. Pérez-Fernández; E. de la Peña; J.M. De La Morena; C. Llorente
INTRODUCTION Active surveillance for prostate cancer has grown systematically in the recent years with more robust mid-term outcomes. However, changes in Gleason score during serial biopsies are not detailed in many of these reports. OBJECTIVES To evaluate changes in Gleason score on follow-up biopsies in low-risk prostate cancer in patients undergoing AS program in our center. MATERIAL AND METHODS Series of patients diagnosed of prostate cancer between 2004 and 2013 have been analyzed. The inclusion criteria were: PSA ≤ 10 ng/ml + Gleason ≤ 6 + T1c/T2a + ≤ 2 positive cores, and no more than 50% of affected core. The pathology of each of the biopsies was analyzed. RESULTS We studied a series of 175 patients undergoing AS. Mean follow-up was 3.96 years (SD 2.4). Follow-up biopsies with Gleason scores ≥ 7 were: 5.72% in the first biopsy, 7.39% and 7.41% in subsequent biopsies. By contrast, in 42.03% of cases did not show evident tumor involvement in the first biopsy, 40.74% and 51.85% in the second and third biopsies respectively. Median stay in the AS program was: 90.99 months (95% CI: 53.53-128.46) in patients with first positive biopsy vs. 96.66 months (95% CI: 63.19-130.13) in those without evidence of tumor. CONCLUSIONS In our series the pathological data of the first 3 biopsies remain stable in terms of the positive biopsy rate, Gleason score, or indication of active treatment proportions. Those patients who do not show evidence of malignancy in the first follow-up biopsy are less likely to need active treatment than the other patients in the series.
The Journal of Urology | 2015
B. López; C. Llorente; V. Hernández; Enrique de la Peña; E. Pérez-Fernández; Maria A. Gogorcena
INTRODUCTION AND OBJECTIVES: Surgeonand hospitalcase volume are identified as factors related with outcomes of surgical procedures. Radical cystectomy (RC), due to its major impact on the patient, might substantially benefit from centralization if this assumption were true. We aim to test this hypothesis in Spain, a country in which no lower limit nor centralization for radical cystectomy exists. METHODS: We performed a retrospective cohort review of patients undergoing RC in Spain during 2011 and 2012, accessing data from inpatient discharge forms (CMBD) of every patient operated on of radical cystectomy. CMBD is a mandatory file that is submitted to the Ministry of Health and provides information on patient’s demographics as well as morbidity and cause of discharge including death. Hospitals were stratified into volume quartiles depending on their 2-year cumulative cystectomy volume (very lowvolume 58). Hospitals were also categorized according to their size in beds and teaching facilities. A comparison with data in the literature was made. RESULTS: We analyzed 5,594 RCs in 266 centers of Spain during 2011 and 2012 (2,701 RCs in 2011 and 2,893 RCs in 2012). Mean age was 66.5 9.8 years and 84.7% were males. Mean hospital stay was 20.7 16.6 days. Mortality rate at 30, 60 and 90 days was 2.8%, 4.7% and 5.9%, respectively. 90-day mortality rate for very-low, low, medium and high-volume centers was 5.9%, 5.9%, 7% and 5.1%, respectively (p1⁄40.2). Hospital size and teaching facilities were not associated with mortality. A statistically significant difference was noted in the complications and readmission rate. These results compare favorably with reported multicenter series in the literature with 90-day mortality rate ranging from 4.2 to 7.9%. CONCLUSIONS: Our data do not support an urgent need for regionalization of radical cystectomy in our country. However, initiatives to improve surgical outcomes of radical cystectomy within individual national setting should be explored.
Eurasia antiqua | 2000
Magomed G. Gadzhiev; Philip L. Kohl; Rabadan G. Magomedov; David Stronach; Shamyl M. Gadzhiev; P. Lopez Garcia; B. López; Alejandra Morales; M. Moreno; J.A. López Sáez; M. Martín Sánchez
Actas Urologicas Espanolas | 2016
A. Guijarro; L. Reguero; V. Hernández; J.M. De La Morena; E. de la Peña; B. López; B. Fernández; C. Parrilla; E. Pérez-Fernández; I. Alemany; C. Llorente
Actas Urologicas Espanolas | 2017
C. Llorente; B. López; V. Hernández; A. Guijarro; E. Pérez-Fernández
Actas Urologicas Espanolas | 2017
C. Llorente; B. López; V. Hernández; A. Guijarro; E. Pérez-Fernández
European Urology Supplements | 2016
C. Llorente; V. Hernández; E. Pérez-Fernández; M.C. Elze; B. López; S. Pocock
Actas Urologicas Espanolas | 2015
A. Guijarro; V. Hernández; B. López; Carlos Capitán; E. Pérez-Fernández; E. de la Peña; J.M. De La Morena; C. Llorente
Actas Urologicas Espanolas | 2014
F.J. Díaz; E. de la Peña; V. Hernández; B. López; J.M. De La Morena; M.D. Martín; I. Jiménez-Valladolid; C. Llorente